Novo Nordisk A/S (NVO) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Novo Nordisk A/S (NYSE: NVO):

• 2/5/2026 – Novo Nordisk A/S was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 2/5/2026 – Novo Nordisk A/S had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 2/5/2026 – Novo Nordisk A/S was given a new $45.00 price target on by analysts at BMO Capital Markets.
• 2/3/2026 – Novo Nordisk A/S had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/27/2026 – Novo Nordisk A/S is now covered by analysts at Citigroup Inc.. They set a “neutral” rating on the stock.
• 1/26/2026 – Novo Nordisk A/S was given a new $57.00 price target on by analysts at BMO Capital Markets.
• 1/22/2026 – Novo Nordisk A/S had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 1/14/2026 – Novo Nordisk A/S had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 1/9/2026 – Novo Nordisk A/S is now covered by analysts at CICC Research. They set an “outperform” rating and a $73.50 price target on the stock.
• 1/9/2026 – Novo Nordisk A/S was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 12/29/2025 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/23/2025 – Novo Nordisk A/S had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/22/2025 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Novo Nordisk A/S was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 52.74%.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.